Peninsula biotech targets $172.5M fundraise after stock doubles from mid-stage study in deadly lung disease


The company is testing a higher-dose version of its drug against idiopathic pulmonary fibrosis, or IPF, in a clinical trial that could deliver results early next year.

Previous Avnet CFO set to retire; replacement named
Next Wine Spectator awards multiple Birmingham restaurants for selection